You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 160 No. 6, March 27, 2000 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Editor's Correspondence
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Eligibility for Outpatient Treatment With Low-Molecular-Weight Heparin in Venous Thromboembolism

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Recently, low-molecular-weight heparin (LMWH) has emerged as a new alternative to unfractionated heparin for the treatment of venous thromboembolic diseases. It possesses several advantages, such as longer half-life and predictable anticoagulant response,1 and its use in outpatient settings can substantially reduce the cost of care.2 In trials investigating the efficacy and safety of LMWH treatment in outpatient settings, different exclusion criteria for patient selection were introduced. Some studies excluded more than half of the patients.3-4 In a recent issue of the ARCHIVES, Wells et al5 proved that more than 80% of their patients could be treated safely and effectively as outpatients. The Albert Einstein Medical Center, Philadelphia, Pa, is a tertiary-care hospital, providing care in an urban setting. The eligibility rate for outpatient LMWH therapy in an institution such as ours is unknown.

We retrospectively reviewed the medical records of patients who had a confirmed diagnosis of deep vein thrombosis . . . [Full Text of this Article]

Corresponding author: Tawee Tanvetyanon, MD, Albert Einstein Medical Center, 5501 York Rd, Klein Suite 331, Philadelphia, PA (e-mail: tan73@hotmail.com).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Treatment of Proximal Vein Thrombosis With Subcutaneous Low-Molecular-Weight Heparin vs Intravenous Heparin: An Economic Perspective
Russell D. Hull, Gary E. Raskob, David Rosenbloom, Graham F. Pineo, Robert G. Lerner, Amiram Gafni, Arthur A. Trowbridge, C. Gregory Elliott, David Green, Joseph Feinglass, William Feldstein, and Rollin Brant
Arch Intern Med. 1997;157(3):289-294.
ABSTRACT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review
Squizzato et al.
Eur Respir J 2009;33:1148-1155.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.